These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9194992)

  • 1. Precipitation of amphotericin B from i.v. fat emulsion.
    Heide PE
    Am J Health Syst Pharm; 1997 Jun; 54(12):1449. PubMed ID: 9194992
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment: compatibility of amphotericin B with lipid emulsions.
    Montoro JB; López RM; Pou L
    Ann Pharmacother; 1996 Dec; 30(12):1501. PubMed ID: 8968472
    [No Abstract]   [Full Text] [Related]  

  • 3. Amphotericin B formulated in a lipid emulsion.
    Cleary JD
    Ann Pharmacother; 1996 Apr; 30(4):409-12. PubMed ID: 8729899
    [No Abstract]   [Full Text] [Related]  

  • 4. Stability of amphotericin B in an extemporaneously prepared i.v. fat emulsion.
    Lopez RM; Ayestaran A; Pou L; Montoro JB; Hernandez M; Caragol I
    Am J Health Syst Pharm; 1996 Nov; 53(22):2724-7. PubMed ID: 8931814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of amphotericin B 0.05 and 0.5 mg/mL in 20% fat emulsion.
    Owens D; Fleming RA; Restino MS; Cruz JM; Hurd DD
    Am J Health Syst Pharm; 1997 Mar; 54(6):683-6. PubMed ID: 9075499
    [No Abstract]   [Full Text] [Related]  

  • 6. Comments concerning 'The penetration of amphotericin B from an Intralipid formulation into fibrin loci in a rabbit model of candidiasis'.
    Washington C; Davis SS
    Biopharm Drug Dispos; 1995 Aug; 16(6):529-31. PubMed ID: 7579034
    [No Abstract]   [Full Text] [Related]  

  • 7. Amphotericin B does not mix with fat emulsion.
    Trissel LA
    Am J Health Syst Pharm; 1995 Jul; 52(13):1463-4. PubMed ID: 7671046
    [No Abstract]   [Full Text] [Related]  

  • 8. [Amphotericin B into parenteral lipid emulsions. Galenic stability of mixtures. Preliminary results].
    Blancard A; Monges P; Lacarelle B; Denis JP; Bongrand MC; Ragon CH; Gouin F
    Pathol Biol (Paris); 1996 May; 44(5):384-8. PubMed ID: 8758481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amphotericin B in fat emulsion.
    Kintzel PE
    Am J Health Syst Pharm; 1996 Nov; 53(22):2701. PubMed ID: 8931810
    [No Abstract]   [Full Text] [Related]  

  • 10. Amphotericin B infused in 20% lipid emulsion.
    Ryan KA
    J Intraven Nurs; 1996; 19(3):123-5. PubMed ID: 8788829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amphotericin B intralipid formulation: stability and particle size.
    Ranchère JY; Latour JF; Fuhrmann C; Lagallarde C; Loreuil F
    J Antimicrob Chemother; 1996 Jun; 37(6):1165-9. PubMed ID: 8836819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute renal failure with amphotericin B in lipid emulsion.
    Gales MA; Gales BJ; Alford KM
    Ann Pharmacother; 1996 Sep; 30(9):1036. PubMed ID: 8876871
    [No Abstract]   [Full Text] [Related]  

  • 13. Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia.
    Pascual B; Ayestaran A; Montoro JB; Oliveras J; Estibalez A; Julia A; Lopez A
    Ann Pharmacother; 1995 Dec; 29(12):1197-201. PubMed ID: 8672820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case-control study of amphotericin B in a triglyceride fat emulsion versus conventional amphotericin B in patients with AIDS.
    Manfredi R; Chiodo F
    Pharmacotherapy; 1998; 18(5):1087-92. PubMed ID: 9758320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma protein adsorption patterns on surfaces of Amphotericin B-containing fat emulsions.
    Schmidt S; Müller RH
    Int J Pharm; 2003 Mar; 254(1):3-5. PubMed ID: 12615399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oral delivery of amphotericin B.
    Torrado JJ; Serrano DR; Uchegbu IF
    Ther Deliv; 2013 Jan; 4(1):9-12. PubMed ID: 23401912
    [No Abstract]   [Full Text] [Related]  

  • 17. [Use of amphotericin B in lipid emulsions: does it prevent its toxicity in critically ill patients?].
    Hernández G; Altermatt F; Bernucci F; Acuña D; Apablaza F; Valenzuela F; Lefio A; Pérez C; Bugedo G; Castillo L
    Rev Med Chil; 2000 Oct; 128(10):1101-7. PubMed ID: 11349508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comment: expense of amphotericin B product.
    Andersen JM
    Ann Pharmacother; 1996 Nov; 30(11):1342. PubMed ID: 8913426
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of intralipid as a vehicle for amphotericin B in the treatment of cryptococcal meningitis in a renal transplant recipient.
    Nicol AJ; Cassidy MJ; Michalowsky K; Kahn D
    Nephron; 1996; 73(2):312-3. PubMed ID: 8773363
    [No Abstract]   [Full Text] [Related]  

  • 20. Structure and toxicity of amphotericin B/triglyceride emulsion formulations.
    Lance MR; Washington C; Davis SS
    J Antimicrob Chemother; 1995 Jul; 36(1):119-28. PubMed ID: 8537259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.